ASH 2015 – Castleman’s Disease, Lymphoma, and CLL

Obinutuzumab plus Ibrutinib as Induction and Maintenance Therapy After Bendamustine Debulking in Patients with CLL: Interim Results of a Phase 2 CLL2-BIG Trial

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Ibrutinib versus Chlorambucil in Patients >65 Years with Treatment-Naïve CLL/SLL: Results from the Phase 3 RESONATE-2 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Obinutuzumab plus Bendamustine in Previously Untreated Patients with CLL: Subgroup Analysis of the Phase 3 GREEN Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Phase 2 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Ibrutinib versus Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle-Cell Lymphoma (MCL)

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Syk Inhibitor Entospletinib Monotherapy in CLL/SLL: Phase 2 Trial Results

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Outcomes of Ibrutinib Treatment in Patients with Relapsed or Refractory CLL/SLL with del17p in the RESONATE-17 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Idelalisib plus Bendamustine/Rituximab versus Bendamustine/Rituximab in Relapsed/Refractory CLL: Results of a Phase 3 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Rituximab, Lenalidomide, and Ibrutinib as Frontline Therapy in Follicular Lymphoma: Results of the ALLIANCE 051103 Phase 1 Study

ASH 2015 – Castleman’s Disease, Lymphoma, and CLL, ASH Highlights

Conference Correspondent

Page 2 of 2

1
2